51 results
8-K
EX-99.2
CCCC
C4 Therapeutics, Inc.
14 Jan 25
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
7:09am
% 75% 100% All PTCL (N=16) AITL (N=4) ALCL (N=2) ATLL (N=5) PTCL-NOS (N=5) B e st R e sp o n se % ( N ) CMR PMR PET-CT–based Assessment of PMR … evaluated based on CT scan and were PD but not evaluable based on PET-CT, both patients are included as PMD for PET-CT based assessment; 2 additional
8-K
EX-99.1
CCCC
C4 Therapeutics, Inc.
9 Dec 24
Other Events
9:49am
) AITL (N=4) ALCL (N=2) ATLL (N=5) PTCL-NOS (N=5) B e st R e sp o n se % ( N ) CMR PMR PET-CT–based Assessment of PMR or Better by PTCL Subtype* (N=16) ORR … based on CT scan and were PD but not evaluable based on PET-CT, both patients are included as PMD for PET-CT based assessment; 2 additional subjects
8-K
EX-99.3
CCCC
C4 Therapeutics, Inc.
9 Dec 24
Other Events
9:49am
=2) ATLL (N=5) PTCL-NOS (N=5) B e st R e sp o n se % ( N ) CMR PMR PET-CT–based Assessment of PMR or Better by PTCL Subtype* (N=16) ORR 20% ORR 20% ORR … based on PET-CT, both patients are included as PMD for PET-CT based assessment; 2 additional subjects that came off study prior to follow up scans
424B5
CCCC
C4 Therapeutics, Inc.
15 Nov 24
Prospectus supplement for primary offering
4:05pm
” disclosure; reduced disclosure about our executive compensation arrangements; exemption from the auditor attestation requirement in the assessment of our
SUPPL
CCCC
C4 Therapeutics, Inc.
13 Nov 24
Supplemental materials (foreign)
4:58pm
” disclosure; reduced disclosure about our executive compensation arrangements; exemption from the auditor attestation requirement in the assessment of our
S-3
EX-4.3
vbx ia3mdhkfmvxgzaa0
31 Oct 24
Shelf registration
5:26pm
S-3
75v8tn17
31 Oct 24
Shelf registration
5:26pm
S-3
EX-4.5
36zc55pm0xsd3fbe
31 Oct 24
Shelf registration
5:26pm
S-3
EX-1.2
fmzz0nrezc zaq
31 Oct 24
Shelf registration
5:26pm
ARS
ua19vvb2
30 Apr 24
Annual report to shareholders
8:52am
8-K
EX-10.2
nqyjn
30 May 23
Entry into a Material Definitive Agreement
7:30am
ARS
pph5r709owy 8gw
28 Apr 23
Annual report to shareholders
7:03am